Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
81-100 of 1,694 trials

Breast Cancer: Ribociclib with Hormone Therapy and Radiotherapy

We are studying the safety and effectiveness of Ribociclib combined with hormone therapy and radiotherapy for elderly patients with hormone-positive, HER2-negative breast cancer. This trial is for those newly diagnosed who are not ready for surgery.

Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Osimertinib (TAGRISSO) Continuation Study

We are providing ongoing treatment with osimertinib for patients who have benefited from it in a previous study. The goal is to monitor safety and tolerability as they continue their treatment.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Fertility Treatment: Progesterone Support in IUI

We are studying if adding progesterone support helps couples with unexplained infertility achieve higher live birth rates during intra-uterine insemination. We also want to see if this approach is cost-effective and safe.

Female Infertility and Subfertility1-2 yearsMonitoring phase (IV)Investigational MedicinesEndocrinologyGynecology and Obstetrics

High-Risk Prostate Cancer: THUNDER Trial

We are studying new diagnostic tracers and treatment options for men with high-risk prostate cancer. The goal is to see if these methods improve survival and quality of life compared to standard treatments.

Prostate Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesOncologyUrology

Richter Syndrome: GLOfitamab with Chemotherapy

We are studying a new treatment combining GLOfitamab with standard chemotherapy for patients with Richter syndrome. The goal is to see if this combination improves treatment response and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Stroke Prevention in Kidney Disease: Apixaban Study

We are studying whether apixaban can safely reduce the risk of strokes in patients with chronic kidney disease stage 5 and atrial fibrillation. This trial will help us understand its effects compared to standard care.

Atrial Fibrillation with Chronic Kidney Disease Stage 5>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal MedicineNephrology

Staphylococcal Joint Infection: Rifampicin vs. Clindamycin

We are studying whether a targeted antibiotic can effectively treat staphylococcal infections in joint prostheses compared to a traditional combination therapy. This trial also examines quality of life and any side effects experienced by participants.

Prosthetic Joint Infection1-2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesOrthopedics and Traumatology

Itacitinib: Continued Treatment Study

We are providing ongoing treatment for participants who have benefited from itacitinib in earlier studies. This study aims to evaluate the safety of continued use of this medication.

Chronic Graft Versus Host DiseaseBronchiolitis Obliterans SyndromeMyelofibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicineOncology

Kidney Transplant: Belatacept vs. Calcineurin Inhibitors

We are studying whether switching to a new immunosuppressive medication helps adolescent kidney transplant recipients maintain their health better than staying on their current treatment. This trial focuses on patients aged 12 to under 18 years.

Kidney Transplant>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Continued Treatment with Parsaclisib for Blood Disorders

We are providing ongoing treatment for patients who have previously participated in studies of parsaclisib. The goal is to evaluate the safety of this medication alone or with other therapies.

Advanced CancerAutoimmune Hemolytic AnemiaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Major Depressive Disorder: Minocycline vs. Celecoxib

We are studying whether minocycline or celecoxib can help patients with Major Depressive Disorder who haven't responded to previous treatments. The trial will compare how well these medications work and how patients respond to them.

Major Depressive Disorder≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPsychiatry

Metformin Transfer in Breast Milk: A Study for Lactating Women

We are investigating how metformin, used for Type 2 Diabetes, transfers into breast milk and affects breastfeeding infants. This research aims to ensure the safety of breastfeeding while on this medication.

Type 2 Diabetes and Gestational Diabetes≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyPediatrics

Chronic Lymphocytic Leukemia: Nemtabrutinib Study

We are comparing a new treatment called nemtabrutinib to standard options for patients with untreated chronic lymphocytic leukemia. The study aims to find out which treatment works better and is safer.

Small Lymphocytic Lymphoma (SLL) / Chronic Lymphocytic Leukemia (CLL)6-12 monthsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Non-Clear Cell Kidney Cancer: XL092 + Nivolumab

We are studying a new treatment combination for patients with advanced or metastatic non-clear cell kidney cancer. The goal is to see if it works better and is safer than the standard treatment.

Advanced Non-Clear Cell Renal Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

COVID-19 Treatment: LTX-109 Nasal Spray Study

We are testing a new nasal spray for people with COVID-19 or similar symptoms to see if it helps them recover faster and clear the virus. The study will also monitor safety and overall wellbeing during treatment.

Respiratory Tract InfectionCOVID-19COVID-like Illness≤3 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesPulmonology

T-Cell Lymphoma: Autologous Stem Cell Transplantation Study

We are investigating whether autologous stem cell transplantation helps patients with T-cell lymphoma who have responded well to initial chemotherapy. This study aims to see if it improves their chances of staying cancer-free longer.

Peripheral T-cell Lymphoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOncology

Irritable Bowel Syndrome: Ebastine vs. Mebeverine

We are comparing the effectiveness of ebastine and mebeverine for treating irritable bowel syndrome. The study also looks at how these treatments impact quality of life for patients.

Irritable Bowel Syndrome3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesGastroenterologyInternal Medicine

Mantle Cell Lymphoma: Venetoclax with Ibrutinib and Rituximab

We are studying a new treatment combination for patients with Mantle Cell Lymphoma who cannot undergo high-dose therapy. The goal is to see how well it works compared to standard chemotherapy.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Marginal Zone Lymphoma: Mosunetuzumab-Lenalidomide Study

We are investigating whether the combination of Mosunetuzumab and Lenalidomide is more effective than standard treatments for patients with relapsed or refractory Marginal Zone Lymphoma. The study aims to assess how well this new treatment works and its safety.

Marginal Zone Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Psilocybin for Hospitalized Patients with Treatment-Resistant Depression

We are studying the safety and feasibility of psilocybin-assisted psychotherapy for patients with treatment-resistant depression in a hospital setting. This research aims to explore its effects on depression and the overall experience of patients.

Treatment-Resistant DepressionEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemotePsychiatry